KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Other Operating Expenses: 2012-2024

Historic Other Operating Expenses for Alnylam Pharmaceuticals (ALNY) over the last 9 years, with Dec 2024 value amounting to $323.4 million.

  • Alnylam Pharmaceuticals' Other Operating Expenses rose 132.99% to $200.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $517.0 million, marking a year-over-year increase of 68.72%. This contributed to the annual value of $323.4 million for FY2024, which is 4.18% up from last year.
  • As of FY2024, Alnylam Pharmaceuticals' Other Operating Expenses stood at $323.4 million, which was up 4.18% from $310.4 million recorded in FY2023.
  • In the past 5 years, Alnylam Pharmaceuticals' Other Operating Expenses registered a high of $323.4 million during FY2024, and its lowest value of $78.1 million during FY2020.
  • For the 3-year period, Alnylam Pharmaceuticals' Other Operating Expenses averaged around $267.5 million, with its median value being $310.4 million (2023).
  • Data for Alnylam Pharmaceuticals' Other Operating Expenses shows a peak YoY surged of 211.44% (in 2020) over the last 5 years.
  • Alnylam Pharmaceuticals' Other Operating Expenses (Yearly) stood at $78.1 million in 2020, then surged by 79.55% to $140.1 million in 2021, then climbed by 20.46% to $168.8 million in 2022, then surged by 83.87% to $310.4 million in 2023, then rose by 4.18% to $323.4 million in 2024.